Melanotan 2 10 mg
Melanotan II Dragon Pharma — Overview
Melanotan II Dragon Pharma is a synthetic cyclic analogue of alpha-melanocyte stimulating hormone (α-MSH) designed for subcutaneous injection. It activates melanocortin receptors in the skin and central nervous system, producing two primary effects: accelerated melanogenesis (skin darkening) and MC4 receptor-mediated enhancement of libido and sexual function. Unlike sunbed tanning, Melanotan II stimulates pigment production directly at the cellular level, requiring significantly less UV exposure to produce a visible tan.
Each Dragon Pharma vial contains 10 mg of lyophilized Melanotan II. This page covers the melanocortin receptor system and how MT-II engages it, the compound's documented effects on pigmentation and sexual function, the loading and maintenance protocol, product positioning relative to PT-141, and side effect management.
About the Compound: Melanotan II
Alpha-melanocyte stimulating hormone (α-MSH) is an endogenous peptide derived from proopiomelanocortin (POMC) that acts on five melanocortin receptor subtypes (MC1R through MC5R). In the skin, MC1R activation on melanocytes triggers the intracellular signaling cascade that upregulates eumelanin (brown/black pigment) production — the same mechanism that produces tanning after UV exposure, but initiated pharmacologically rather than by UV-induced DNA stress signaling. In the central nervous system, MC4R activation in the hypothalamus and limbic system modulates sexual arousal, libido, and, in men, facilitates penile erection through pro-erectile pathways.
Native α-MSH has a very short half-life (minutes) due to rapid enzymatic cleavage and is unsuitable for therapeutic use. Melanotan II is a cyclic heptapeptide analogue — the ring structure confers resistance to proteolytic degradation, extending the half-life to several hours and producing substantially greater receptor potency than the native linear peptide. The cyclization also broadens receptor binding, giving MT-II activity at MC1R, MC3R, MC4R, and MC5R simultaneously. This broad activity is responsible for both the tanning and sexual function effects, and also for most of the compound's side effects.
What Melanotan II Does
Melanotan II produces two mechanistically distinct categories of effects through its melanocortin receptor activity:
- Skin pigmentation (MC1R) — activation of MC1R on melanocytes upregulates tyrosinase enzyme activity and shifts melanin synthesis toward eumelanin (dark brown/black pigment) over phaeomelanin (red/yellow); this produces darkening of the skin that is amplified by any UV exposure, allowing users to achieve a visible tan with significantly shorter sun or tanning bed exposure than would otherwise be required; the pigment change is cumulative and develops progressively over the loading phase
- Libido and sexual function (MC4R) — MC4R activation in the hypothalamus and limbic regions increases sexual arousal and desire in both men and women; in men, MC4R-mediated pathways facilitate spontaneous erections and enhance erectile response to stimulation; the sexual effects occur at lower doses than are typically needed for significant tanning and can appear within hours of the first injection; these effects are the basis of the related peptide PT-141 (bremelanotide)
- Appetite suppression (MC3R/MC4R) — melanocortin receptor activation in the hypothalamus has a secondary appetite-suppressing effect; this is typically mild at tanning doses but may contribute to modest reductions in food intake during the loading phase
- Darkening of existing pigmented lesions — moles, freckles, and other melanocyte-rich lesions respond more strongly to MC1R activation than surrounding skin; pre-existing benign moles typically darken visibly during loading; this is a cosmetic effect of the mechanism but warrants a baseline skin check before starting
Protocol overview: reconstitute the 10 mg vial with 2 mL of Bacteriostatic Water, giving a concentration of 5 mg/mL (0.5 mg = 0.1 mL on an insulin syringe). Loading: inject 0.5–1 mg subcutaneously once daily; combine with modest UV exposure (10–20 minutes of natural sun or a short tanning bed session) to activate melanogenesis — MT-II potentiates UV-triggered pigment production rather than replacing it entirely. Continue loading until the desired level of pigmentation is reached (typically 1–4 weeks). Maintenance: 0.5 mg two to three times per week is sufficient to sustain pigmentation once achieved. The 10 mg vial yields 20 doses at 0.5 mg or 10 doses at 1 mg.
Who It's For
- Individuals wanting to build or maintain a tan with minimal UV exposure — MT-II dramatically lowers the UV dose needed to produce visible pigmentation; it is most practical for people who tan poorly without prolonged sun exposure, who want to maintain a tan year-round without ongoing UV access, or who want to reduce cumulative UV exposure while achieving the same cosmetic result
- Users seeking libido enhancement or support for erectile function — the MC4R-mediated sexual effects are reliable at low doses (0.25–0.5 mg) and occur independently of the tanning response; for users whose primary goal is sexual function rather than pigmentation, on-demand dosing at 0.5–1 mg 1–2 hours before anticipated sexual activity is practical; PT-141 is the MC4R-selective alternative for users who want the sexual effects without any tanning
- Athletes and bodybuilders managing cosmetic appearance — a consistent tan enhances muscle definition visibility on stage or in photos; MT-II allows athletes to maintain competition-ready skin tone during periods with limited sun access (winter training, indoor competition prep) without extended tanning sessions
- Users who should consider alternatives: those with a personal or family history of melanoma or atypical moles should not use MT-II, as MC1R stimulation of existing pigmented lesions carries unpredictable effects; those who want sexual function support without any tanning effect are better served by PT-141, which targets MC4R selectively with no pigmentation activity
Context & Related Products
Melanotan II's broad melanocortin receptor activity places it in a unique position relative to the other peptides in the same functional space:
| Product | Receptor Target(s) | Mechanism vs Melanotan II |
|---|---|---|
| Melanotan II 10 mg (this product) | MC1R, MC3R, MC4R, MC5R | Broad melanocortin agonist; produces both tanning (MC1R) and libido/erectile effects (MC4R) simultaneously; single compound for both goals |
| Melanotan II 5 mg | MC1R, MC3R, MC4R, MC5R | Same compound at half the vial size; lower upfront cost; suitable when maintenance phase is well established and smaller restocking amounts are preferred |
| PT-141 (Bremelanotide) | MC3R, MC4R (selective) | MC4R-selective melanocortin agonist; produces reliable sexual arousal and libido effects with minimal or no pigmentation activity due to low MC1R affinity; used on-demand (1.75 mg intranasally or 1–2 mg SC, 1–2 hours before activity); preferred when tanning is not a goal or when darkening of moles is a concern |
Reconstitution supply:
| Product | Why It's Needed |
|---|---|
| Bacteriostatic Water Dragon Pharma | Required for lyophilized peptide reconstitution. Add 2 mL per 10 mg vial for a working concentration of 5 mg/mL (0.5 mg = 0.1 mL on a standard U-100 insulin syringe). Inject the water slowly down the glass wall — do not shake. Bacteriostatic water preserves the reconstituted solution for 28–30 days refrigerated; protect from light |
Side Effects & Management
Melanotan II's side effects arise from its broad melanocortin receptor activity. The MC4R-mediated effects (nausea, flushing, spontaneous erections) are most pronounced at the start of the loading phase and typically diminish as the body accommodates to the peptide.
| What May Occur | Background | How to Handle It |
|---|---|---|
| Nausea (most common) | MC4R activation in the brainstem area postrema drives nausea, particularly after the first few injections; severity is dose-dependent; most users experience significant nausea at 1 mg but manageable or no nausea at 0.25–0.5 mg; tolerance develops within 1–2 weeks of consistent use | Start at 0.25–0.5 mg and increase only once nausea is minimal at the current dose; inject in the evening so nausea peaks during sleep; take the injection after a meal; Prilosec (Omeprazole) can reduce GI discomfort; avoid lying down immediately after injection as this can worsen nausea for some users |
| Facial flushing | Transient vasodilation in the face and upper body following injection; typically lasts 20–60 minutes; caused by peripheral melanocortin receptor activity; most prominent during loading and diminishes over time | Transient and harmless; typically resolves on its own within an hour; evening dosing reduces the practical impact; drinking water before injection may reduce intensity |
| Spontaneous erections | MC4R pro-erectile signaling is among the most sensitive effects of MT-II; spontaneous erections often occur within 1–4 hours of injection, particularly at higher doses; can be unexpected and inconvenient during loading; tolerance to this effect also develops with continued use | Expected, dose-dependent, and typically resolves with consistent use as receptor sensitivity adapts; lower starting doses (0.25–0.5 mg) reduce the frequency and intensity; evening dosing is practical for this reason |
| Darkening of moles and freckles | Melanocyte-rich lesions contain a higher density of MC1R than surrounding skin; they respond more intensely to MT-II stimulation; pre-existing benign moles typically darken and may increase slightly in size or visibility; this is expected and cosmetically consistent with the tanning effect | Perform a baseline skin assessment before starting; document the appearance of existing moles; monitor any lesion that changes in shape, border, or texture during use — irregular changes in a mole unrelated to simple darkening warrant dermatological evaluation; this is not a reason to avoid MT-II in most users, but it is a reason to not use it if atypical or rapidly changing moles are already present |
| Fatigue and yawning | Central MC4R activity can cause drowsiness or increased yawning shortly after injection; typically mild and resolves within 1–2 hours; more common at higher doses | Mild and transient; evening dosing makes this a non-issue in most cases; if fatigue is pronounced, reduce the dose by 0.25 mg |
| Injection site reactions | Redness or mild induration at the subcutaneous injection site; common to all lyophilized peptides; usually resolves within 24 hours | Rotate sites across abdomen and thigh; use a fine-gauge 29–31G insulin needle; ensure the reconstituted solution is at room temperature before injecting |
References
| Source | Topic | Link |
|---|---|---|
| Life Sciences / PubMed | Dorr et al. 1996 — pilot phase-I clinical study of Melanotan-II; documents tanning activity in humans after low-dose subcutaneous administration and provides early human safety and pharmacological context for the compound | Dorr RT, et al. (1996) ↗ |
| Journal of Urology / PubMed | Wessells et al. 1998 — double-blind, placebo-controlled crossover study showing that Melanotan-II can initiate erections in men with psychogenic erectile dysfunction; establishes the melanocortin-mediated sexual-function pharmacology of the compound | Wessells H, et al. (1998) ↗ |
| Peptides / PubMed | Hadley & Dorr 2006 — review of melanocortin peptide therapeutics covering historical development, clinical studies, receptor pharmacology, pigmentation effects, sexual-function effects, and commercialization milestones for melanocortin analogs including Melanotan compounds | Hadley ME & Dorr RT (2006) ↗ |
| Endocrine Reviews / PubMed | Cone 2006 — authoritative review of melanocortin system physiology covering melanocortin receptors, POMC-derived peptide signaling, pigmentation, adrenocortical steroidogenesis, energy homeostasis, erectile responses, and other melanocortin-regulated functions | Cone RD (2006) ↗ |
| Pigment Cell & Melanoma Research / PubMed | Abdel-Malek 2008 — review of the melanocortin 1 receptor and the UV response of human melanocytes; covers MC1R signaling, melanogenesis, UV-induced apoptosis, DNA damage response, and the role of melanocortins in pigmentation and photoprotection | Abdel-Malek ZA (2008) ↗ |
How to take Melanotan II?
Inject 0.5-1 mg/day initially, then 0.25-0.5 mg for maintenance; see How to Use. Use sterile technique—consult for proper administration.
What is Melanotan II?
Melanotan II is a peptide for tanning and libido enhancement; see What is Melanotan II. It enhances aesthetics—consult professionals for safe use.
What is Melanotan II used for?
It's used for skin tanning and libido enhancement; see Key Benefits. It suits aesthetic goals—use with professional oversight.
How long does Melanotan II stay in your system?
With a 1-2 hour half-life, it's detectable for ~4-6 hours; see Mechanism of Action. Effects persist longer—consult professionals.
Is Melanotan II safe?
It's safe with proper dosing and monitoring; see Side Effects. Manage risks with professional guidance—consult for safety.
How does Melanotan II work?
Melanotan II works by activating melanocortin receptors, which stimulate melanin production in the skin, leading to increased pigmentation over time.
How long does it take to see effects from Melanotan II?
Effects typically develop gradually over several days to weeks depending on dosage, skin type, and sun exposure.
What are the main benefits of Melanotan II?
Commonly discussed benefits include increased skin tanning response, reduced need for UV exposure to achieve pigmentation, and potential appetite and libido modulation effects.
Related Products
- Accelerates muscle and tendon repair for quick recovery.
- Reduces inflammation systemically and locally.
- Enhances joint and tissue resilience for intense training.
- Supports comprehensive healing for uninterrupted performance.
